Loading
A phase 1/2 trial of GC012F in multiple myeloma, run by Gracell Biotechnologies (Shanghai) Co., Ltd., now recruiting.
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT06235229 by Gracell Biotechnologies (Shanghai) Co., Ltd., with 110 participants planned, started 2023-12-26 and due to reach its primary completion in 2026-03-02. Interventions recorded: GC012F. Conditions listed: Multiple Myeloma. No results are recorded here; the registry entry is the source.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Relapsed or refractory multiple myeloma, Multiple myeloma.